Agasta Software is engaged in research, development and commercialization of medical devices
Cipla has received 8 inspectional observations in Form 483
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
The partnership is announced at Aero India 2023, Bangalore
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Themis will market this drug with the brand name REMITHEM.
Subscribe To Our Newsletter & Stay Updated
